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Abstract
Rare variants outside the classical coagulation cascade might cause inherited thrombosis. We
aimed to identify the variant(s) causing venous thromboembolism (VTE) in a family with multiple
relatives affected with unprovoked VTE and no thrombophilia defects. We identified by whole
exome sequencing an extremely rare Arg to Gln variant (Arg89Gln) in the Microtubule Associ-
ated Serine/Threonine Kinase 2 (MAST2) gene that segregates with VTE in the family. Free-tis-
sue factor pathway inhibitor (f-TFPI) plasma levels were significantly decreased in affected family
members compared to healthy relatives. Conversely, plasminogen activator inhibitor-1 (PAI-1)
levels were significantly higher in affected members than in healthy relatives. RNA sequencing
analysis of RNA interference experimental data conducted in endothelial cells revealed that, of
the 13,387 detected expressed genes, 2,354 have their level of expression modified by MAST2
knockdown, including SERPINE1 coding for PAI-1 and TFPI. In HEK293 cells overexpressing
the MAST2 Gln89 variant, TFPI and SERPINE1 promoter activities were respectively lower and
higher than in cells overexpressing the MAST2 wild type. This study identifies a novel thrombo-
philia-causing Arg89Gln variant in the MAST2 gene that is here proposed as a new molecular
player in the etiology of VTE by interfering with hemostatic balance of endothelial cells.
PLOS GENETICS
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Author summary
Venous thromboembolism (VTE) is a multifactorial disease in which the genetic burden
is high. We here present the case of a French family with multiple relatives affected with
unprovoked VTE (i.e. that occurred in the absence of clinical risk factors) in which no
thrombophilia defects had been identified. Adopting a whole exome sequencing
approach, we identified an extremely rare variant located in the Microtubule-associated
serine/threonine-protein kinase-2 (MAST2) gene that perfectly segregates with the VTE
phenotype and that interferes with hemostatic balance of endothelial cells. Our results
pave the way for adding MAST2 to the list of genes to be sequenced and looked for in
thrombophilia families with unprovoked VTE.
Introduction
Venous thromboembolism (VTE) is a multifactorial disease in which the genetic burden can
be characterized by a sibling relative risk of ~2.5 [1] and an estimated heritability between
35%-60% [2]. As for many multifactorial diseases, the spectrum of genetic factors contributing
to VTE susceptibility ranges from common single nucleotide polymorphisms (SNPs) associ-
ated with low-to- moderate genetic effects to private variants segregating within families and
associated with very high relative risk of disease. About thirty common SNPs with minor allele
frequency (MAF) greater than ~1% have so far been reported to associate with the risk of VTE
in the general population, each of them being characterized by an Odds Ratio for disease rang-
ing between 1.06 and 3.0 [3]. Uncommon genetic variants with MAF between 0.1% and 1%
have also been reported such as the THBD c.-151G>T variant [4] or protein S Heerlen [5]. At
the extreme low frequency side of the genetic spectrum reside private variants
(frequencies < 1‰) that are generally ’loss of function’ variants associated with at least a
10-fold increased risk in heterozygote individuals. These variants mainly affect the coagulation
cascade through inherited deficiencies of the three main natural anticoagulants, antithrombin,
protein C and protein S. However, rare variants outside the classical coagulation cascade have
also been proposed to cause severe rare inherited thrombosis generally referred to as inherited
thrombophilia [6]. Their identification has been facilitated by the development of whole
exome/genome sequencing technologies.
Here we present the case of a French family with multiple relatives affected with unpro-
voked VTE (i.e. VTE that occurred in the absence of clinical risk factors) in which no throm-
bophilia defects had been identified. Adopting a whole exome sequencing (WES) approach,
we identified an extremely rare variant located in the Microtubule-associated serine/threo-
nine-protein kinase-2 (MAST2) gene that perfectly segregates with the VTE phenotype. Com-
plementary RNA sequencing (RNA-seq) experiments performed in endothelial cells treated
with siRNAs targeting MAST2 and gene reporter experiments demonstrate, for the first time,
a role of MAST2 in thrombotic processes in particular through its involvement in the regula-
tion of TFPI and SERPINE1 genes.
Results
Pattern of coagulation parameters in the studied family
The genealogical tree of the family with unknown thrombophilia is reported in Fig 1. Measure-
ment of coagulation parameters in family members are reported in Table 1. While differences
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in prothrombin time, International Normalized Ratio (INR), activated partial thromboplastin
time, Factor II (FII), and Factor X (FX) were due to the use of antivitamin K in cases, unex-
pected nominal statistical differences (p< 0.05) were observed for plasma levels of the antico-
agulant protein free-Tissue Factor Pathway Inhibitor (f-TFPI) and the antifibrinolytic protein
Plasminogen Activator Inhibitor-1 (PAI-1). Plasma levels of f-TFPI were significantly
(p = 0.01) lower in the affected family members compared to healthy relatives (6.6 +/- 1.9 ng/
mL vs 17.4 +/- 1.2 ng/mL) (Fig 2) while the opposite pattern was observed for PAI-1 plasma
levels (21.7 +/- 6.1 IU/mL vs 3.3 +/-0.7 IU/mL, p = 0.01) (Fig 2).
Identification of a MAST2 variant following the WES strategy
As the familial transmission of the disease was compatible with an autosomal dominant inheri-
tance, we first selected variants (n = 14,406) shared by all cases and then excluded those that
were carried by controls, leaving 1,153 variants as potential candidates. Among those, 108
were likely functional variants (stop loss/stop gain, frameshift insertion/deletion, non-
Fig 1. Genealogical tree of the family.
https://doi.org/10.1371/journal.pgen.1009284.g001
Table 1. Measurement of coagulation parameters in the 10 subjects with citrated plasma available.
Subjects Status PT (%) INR (ratio) aPTT (sec) Fibrinogen (g/L) FII (%) FV (%) FX (%) f-TFPI (ng/mL) PAI-1 (UI/mL)
305000 case 30 2.55 49.5 4.16 27 64 13 7.4 15
305001 case 26 2.88 46.7 4.3 18 76 9 2.9 16
305002 case 33 2.29 40.1 3.87 29 96 14 9.5 34
305004 control 98 1.01 32.4 4.93 99 86 105 17.2 1
305006 control 93 1.04 39 1.97 82 91 96 17.7 4
350007 control 100 1 35.4 2.62 107 75 122 15.1 1
305010 control 114 0.93 34.3 3.17 103 117 102 17.1 2
305013 control 104 0.98 35.1 3.13 97 95 90 21.9 4
305014 control 98 1.01 33.9 2.66 102 102 98 20.7 5
305015 control 106 0.97 37.8 3.26 95 91 95 12.3 6
PT: prothrombin Time; INR: International Normalized Ratio; aPTT: activated partial thromboplastin time; FII: Factor II; FV: Factor V; FX: Factor X; f-TFPI: free-Tissue
Factor Pathway Inhibitor; PAI-1: Plasminogen activator inhibitor-1
https://doi.org/10.1371/journal.pgen.1009284.t001
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Fig 2. Free-TFPI (f-TFPI), euglobulin clot lysis time (ECLT), Plasminogen Activator Inhibitor-1 (PAI-1) and Urokinase (UPA)
plasma levels in VTE cases and controls from the family. Statistical analyses were made using Mann-Whitney. � p<0.05 and
��p<0.01: significant vs controls.
https://doi.org/10.1371/journal.pgen.1009284.g002
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synonymous and splicing) that we selected for further investigations. Then bioinformatics
search in public genomic data repositories identified 2 as very rare candidates. One,
rs151257275, was a nonsynonymous Arg to Gln variant in the ADAMTS10 gene, with allele
frequency ~0.005 and predicted to have no deleterious effect on the protein function. The sec-
ond, rs1387081220 is a nonsynonymous Arg to Gln mutation (Arg89Gln) in exon 2 of the
MAST2 gene and it has 2 independent heterozygous cases reported in gnomAD[7].
These two candidate variants were then genotyped in all individuals, including those used
for WES and their relatives with available DNA that were not part of the WES analysis (1 case
and 8 controls). Only the MAST2 variant perfectly co-segregated with the VTE phenotype
whereas one case (305012) did not carry the ADAMTS10 variant indicating that this variant
should no longer be a candidate (S1 Table).
We genotyped the uncharacterized MAST2 variant in 6,790 VTE cases and 5,970 healthy
individuals and did not detect additional carriers providing strong argument that this variant
was extremely rare. The look-up performed in other large cohort studies (i.e. 100,000 Genomes
Project, gnomAD, NIHR BioResource-Rare Diseases, H3-Africa and GenomeAsia 100K; S2
Table, which includes relevant references) showed that the MAST2 Arg89Gln variant was only
present in 2 alleles out of the ~ 345,000 total sequences in these projects (S2 Table).
In silico prediction tools considered this variation to be of strong deleteriousness (SIFT: del-
eterious, Polyphen: probably damaging, CADD score ranging from 27 to 34 according to refer-
ence database/versions). However, the predicted functional impact of the variant is rather
unknown. It is not estimated to affect splicing mechanisms as assessed by QUEPASA, HEX-
plorer and HAL softwares [8]. The variant is located in a very conserved region and affects
amino acid (AA) 89 in the exon 2 of the gene, outside the two known protein domains of the
molecule, a Protein Kinase domain ranging from 512AA to 854AA and a PDZ domain from
1104AA to 1192AA.
Functional characterization of the mutation and its structural gene
The observation that plasma concentrations of f-TFPI and PAI-1 (two proteins produced by
the endothelium) were significantly associated with the presence of the MAST2 Arg89Gln vari-
ant, led us to propose the involvement of MAST2 in regulating some endothelial properties.
To gain a deeper understanding of the impact of this critical, yet relatively unknown contribu-
tor of endothelial homeostasis, an RNA-Seq based analysis was performed to compare the
mRNA expression profiles of ECV 304 endothelial cells, with those of MAST2 knockdown
cells. The heatmap (Fig 3A) and volcano plot (Fig 3B) showed global expression changes in
MAST2 knockdown cells. The full list of differential association p-value is given in S3 Table.
Of the 13,387 expressed genes that have been detected, 2,354 have their expression modified
(FDR< 1%) by MAST2 knockdown. As expected, MAST2 was one of the genes which expres-
sion was the most significantly reduced (ranked 8 in terms of differential association p-value;
log2 fold change (log2FC) ~ -2). The expression of RHBLD2 was the most reduced (ranked
689; log2FC– 4.3) and that of HIST1H2BB the most increased (ranked 897; log2FC 3.53) by
MAST2 knockdown. The expression of some genes known to regulate the hemostatic proper-
ties of endothelial cells was altered by MAST2 knockdown. This was the case for SERPINE1
(coding for PAI-1) (ranked 42; log2FC ~ -1.26), PLAU (coding for urokinase) (ranked 85;
log2FC -2), SERPIN B8 (ranked 22; log2FC 1.42) (a serine protease inhibitor hypothesized to
co-express with PLAU as evidenced by text mining search tools, see Materials and Methods),
and TFPI (ranked 1697; log2FC ~0.60). The expression of PLAT (coding for tissue plasmino-
gen activator, t-PA) and THBD (coding for thrombomodulin), two genes also involved in the
regulation of endothelial function, was not significantly altered.
PLOS GENETICS MAST2 and venous thrombosis
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Real-time PCR analyses (Fig 3C) confirmed most of the RNA-Seq findings observed for
aforementioned genes. Treatment of endothelial cells with siRNA specific for MAST2
decreased the expression of MAST2, RHBDL2, SERPINE1, PLAU and increased the expression
of HIST1H2BB, TFPIα and TFPIβ. PLAT expression was also observed to be significantly
decreased, but to a smaller extent, and THBD expression was not significantly modified (Fig
3C). These results underline the ability of MAST2 to regulate mRNA levels of genes encoding
proteins involved in coagulation/fibrinolysis cascades.
Pathway analysis was then applied to the top 100 most significantly differentiated mRNA
expressions according to MAST2 silencing to assess whether this genes list could be enriched
for genes belonging to specific biological pathways. Enrichment analysis was performed using
the DAVID software [9] interrogating the GO, KEGG, REACTOME, and PANTHER data-
bases. At a FDR of 1%, very few pathways were identified (Fig 4A and S4 Table). Nevertheless,
one of these pathways was significantly enriched (FDR = 0.002) for genes belonging to the
fibrinolysis cascade notably SERPINE1, PLAU and SERPINB8.
Because pathway structure and terminology vary across databases, we determined which
genes were significantly contributing to the overall pathway signals detected. A comparison of
the significant differently expressed genes from significant BioCarta, GO, KEGG and Reac-
tome pathways converged on two genes (PLAU and BIRC2 Fig 4B). BIRC2 codes for a E3 ubi-
quitin-protein ligase (Baculoviral IAP Repeat Containing 2 protein) involved in many
biological processes including apoptosis and response to inflammatory and virus stimuli. A
direct role of this protein in coagulation, if any, has never been documented. Conversely,
Fig 3. (A) Heatmap of the 5000 genes most differently expressed between cells treated with control siRNA (lanes 1–3)
and with MAST2 specific siRNA (lanes 4–6). (B) volcano plot. (C) Validation of the RNA-seq. ECV304 cells were
transfected with control siRNA or with two MAST2 specific siRNA. 48 hours post transfection, mRNA levels of
MAST2, RHBDL2, HIST1H2BB (HIST1), TFPIα and β, SERPINE1, PLAU, PLAT, THBD and SERPINB8 were
analyzed by RT-PCR. Data are means ± Standard Deviation. Statistical analyses were made using unpaired t-test.
���p<0.001: significant vs control.
https://doi.org/10.1371/journal.pgen.1009284.g003
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PLAU codes for the plasminogen activator Urokinase a key molecule of the fibrinolytic path-
way [9]. We thus measured plasma UPA levels in the family members and observed that they
were similar in cases and controls (Fig 2). Interestingly, SERPINE1 was found at the intersec-
tion of significant BioCarta, GO and Reactome pathways (Fig 4B). Plasminogen activation
potential assessed in plasma by the global fibrinolysis assay ECLT was significantly lower in
cases than in controls (1200 +/- 300 Min vs 458 +/- 90 Min, p = 0.01) reinforcing the potential
alteration the fibrinolysis cascade (Fig 2).
Impact of MAST2 Arg89Gln variant on the regulation of TFPI and
SERPINE1 gene expression
Alterations in plasma levels of PAI-1 and TFPI measured in carriers of the MAST2 Arg89Gln
variant (Fig 2) associated with the regulatory role of MAST2 on the expression of the TFPI and
SERPINE1 genes (Fig 3C) led us to hypothesize an effect of the MAST2 Arg89Gln variant on
the expression of these genes. To test this hypothesis, the expression of SERPINE1 and TFPI
was measured in ECV304 cells transfected with expression vector for wild type MAST2 or
MAST2 Gln89 (Fig 5A). We observed that more PAI-1 accumulated (over a period of 36h) in
the conditioned medium from ECV304 cells overexpressing MAST2 Gln89 than in the
medium from cells overexpressing wild-type MAST2 (Fig 5B). TFPI concentrations measured
in ECV304 cells conditioned media were close to the low detection limit of our ELISA assay,
which prevented us from showing any effect of MAST2 overexpression on TFPI expression.
Forty-eight hours after transfection of MAST2 and MAST2 Gln89, RT-PCR analysis showed
no alterations in the mRNA levels of SERPINE1 and TFPI. It is important to mention that at
best 50% of ECV304 cells were transiently transfected, this “relatively low” transfection rate
could be responsible for our inability to detect the effect of the over-expressed proteins on
SERPINE1 and TFPI mRNA levels. Therefore, MAST2-dependent transcriptional regulation
of TFPI and SERPINE1 expression was studied in HEK293 cells expressing firefly luciferase
Fig 4. (A) Scatter plot of Reactome pathways enrichment statistics. Rich factor is the ratio of the differentially
expressed gene number to the total gene number in a certain pathway. q value is corrected p value. The color and size
of the dots represent the range of the q value and the number of differently expressed genes mapped to the indicated
pathways, respectively. (B) Venn diagram showing the overlap of genes of the enriched biological pathways identified
using BioCarta, GO, KEGG and Reactome pathway databases (S4 Table).
https://doi.org/10.1371/journal.pgen.1009284.g004
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under the control of TFPI promoter (TFPI-Luc) or destabilized EGFP under the control of
SERPINE1 promoter (PAI-1-dEGFP). Transfection of MAST2 specific siRNA, which moder-
ately reduced MAST2 protein levels as observed in Fig 6A, significantly increased TFPI pro-
moter activity and reduced that of SERPINE1 (Fig 6B), showing the ability of MAST2 to
regulate the transcription of these genes. To investigate the effect of MAST2 Arg89Gln variant
on TFPI and SERPINE1 transcription, wild type MAST2 and MAST2 Gln89 were overex-
pressed in HEK293 cells (Fig 6C) and their impact on the activity of TFPI and SERPINE1 pro-
moter was analyzed. TFPI promoter activity was lower and that of SERPINE1 higher in cells
overexpressing MAST2 Gln89 than in cells overexpressing wild type MAST2 (Fig 6D). This
result suggests that the transcription of the TFPI and SERPINE1 genes is altered in carriers of
the MAST2 Arg89Gln variant.
Impact of MAST Arg89Gln variant of AKT phosphorylation
There is evidence in the literature for possible connections between MAST2 and phosphatase
and tensin homologue deleted on chromosome 10 (PTEN)[10]. Since PTEN acts as a negative
regulator of PI3K/AKT signaling, we explored the effect of overexpressed MAST2 and MAST2
Gln89 (Fig 5A) on AKT phosphorylation. Total amount of cellular PTEN was similar whether
wild type MAST2 or MAST2 Gln89 was overexpressed (Fig 7A and 7B). However, we detected
more phosphorylated AKT Ser473 when MAST2 Gln89 was overexpressed (Fig 7A–7C), sug-
gesting that PI3K/AKT signaling may be affected by the MAST2 Arg89Gln variant.
Discussion
Using a WES approach, we identified the MAST2 Arg89Gln variant as the disease causing vari-
ant responsible for inherited thrombophilia in an extended family of French origin.
The identification of this variant, located in exon2 of the MAST2 gene, lead us to demon-
strate for the first time that this gene is an important player of endothelium in VTE by
Fig 5. Effect of MAST2 overexpression on PAI-1 production. ECV304 cells were transfected with empty vector (ev),
wild type MAST2 or MAST2 Gln89 expression vector. (A) MAST2 mRNA levels were measured by RT-PCR and
expressed relative to ev transfected cells. (B) PAI-1 accumulated in the culture media over a period of 36 hours was
measured by ELISA and expressed relative to the amount of protein contained in the cell lysate. Data are
means ± Standard Deviation. Statistical analyses were made using t-test. ��p<0.01.
https://doi.org/10.1371/journal.pgen.1009284.g005
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regulating key coagulation and fibrinolysis parameters. This mutation, with allele frequency of
~0,0004% in public genome/exome genomics resources, was not identified in a collection of
~6,790 VTE cases and 5,970 controls specifically genotyped for. According to the ACMG clas-
sification [11], this variation satisfies PP1 and PP3 criteria and would be classified as likely
pathogenic. The identified mutation maps to the N-terminal domain of the MAST2 protein
belonging to the Microtubule-associated serine/threonine-protein kinase (MAST) family. It is
located in a highly conserved region across species and is predicted to be damaging by several
Fig 6. MAST2 regulates TFPI and SERPINE1 promoter activity. (A). HEK293 cells were transfected with control
siRNA or with the two MAST2 specific siRNA and MAST2 expression was analyzed by western blot 48 hours post
transfection. The detection of β-actin attests for equal protein loading. (B). HEK293 cells were cotransfected with
control siRNA or with the two MAST2 specific siRNA together with TFPI (left) or SERPINE1 (right) promoter
reporter. 48 hours post transfection, the activity of the promoters was measured as described in Materials and Methods
section. (C). HEK293 cells were transfected with empty vector (ev), wild type MAST2 or MAST2 Gln89 expression
vector and MAST2 expression was analyzed by western blot 48 hours post transfection. The detection of β-actin attests
for equal protein loading. (D). HEK293 cells were cotransfected wild type MAST2 or MAST2 Gln89 expression vector
together with TFPI (left) or SERPINE1 (right) promoter reporter then the activity of the promoters was measured as in
Fig 4B. Data are means ± Standard Deviation. Statistical analyses were made using Mann-Whitney. ��p<0.01;
���p<0.001: significant vs control.
https://doi.org/10.1371/journal.pgen.1009284.g006
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prediction tools. The members of the MAST kinases family are characterized by the presence
of a serine-threonine kinase domain, a second 3’ MAST domain with some similarity to kinase
domains and a PDZ domain [12]. They were demonstrated to link and phosphorylate the dys-
trophin/utrophin (DMD/UTRN) network with microtubule filaments via the syntrophins,
modulating their affinities for associated proteins[13]. This poorly understood family of pro-
teins has been implicated in several human diseases, such as neurodegeneration and breast
cancer [14]. Our study is the first to report the involvement of MAST kinases in haemostasis.
According to the Human Proteins Atlas and GTEx (http://www.proteinatlas.org; https://
gtexportal.org), MAST2 is mainly expressed in the skeletal muscle but also in many other tis-
sues. At the cellular level, MAST2 is mainly expressed in the cytosol with no major cell
specificity.
By screening several coagulation parameters in the investigated family members, we
observed that carriers of the mutation exhibited decreased TFPI plasma levels compared to
non-carriers while the opposite pattern was observed for PAI-1. Those 2 molecules, which
plasma levels are not affected by vitamin K antagonists, are both synthesized by endothelial
cells and are major components of the coagulation/fibrinolysis process as TFPI is the primary
inhibitor of the initiation of blood coagulation whereas PAI-1 is the main inhibitor of plasmin-
ogen activation. Microtubules are crucial components of the cytoskeleton which controls
endothelial cell shape, migration and proliferation[15]. In plasma, decreased in f-TFPI and
increased in PAI-1 levels are both associated with the risk of thrombosis [16]. According to
these observations, we speculated that MAST2 might play an important role in regulating the
hemostatic function of endothelial cells and that the identified variant interferes with the coag-
ulation/fibrinolysis process affecting the risk of thrombosis. Knockdown experiments per-
formed in ECV304 endothelial cell line followed by RNA-seq analysis confirmed that MAST2
participates to the regulatory mechanisms associated with the dissolution of fibrin clot through
some mechanisms that need to be clarified. This is consistent with the altered ECLT in cases
which is considered as a useful global fibrinolysis assay assessing plasminogen activation
potential [17]. Nevertheless, we showed that MAST2 acts as a negative regulator of TFPI
expression and a positive regulator of that of SERPINE1, PLAU and RHBLD2 coding for the
transmembrane protease that cleaves thrombomodulin at the cell surface[18].
It is quite difficult to transiently transfect a high percentage of EC304 cells with an expres-
sion vector. Moreover, these cells produce minute amounts of TFPI. These two features may
explain why we did not detect any effect of the overexpression of wild type MAST2 or MAST2
Fig 7. Effect of MAST2 on pAKT. ECV304 cells were transfected with empty vector (ev), wild type MAST2 or MAST2
Gln89 expression vector. 48 h post transfection cells were lysed then, AKT, phosphoAKT (pAKT), PTEN and β-actin
(loading control) were detected by immunoblots (A). Chemiluminescent signals were analyzed by densitometry and
ratios PTEN/β-actin (B) and pAKT/AKT (C) were calculated and expressed relative to ev transfected cells. Data are
means ± Standard Deviation. Statistical analyses were made using Mann Whitney test. �p<0.05.
https://doi.org/10.1371/journal.pgen.1009284.g007
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Gln89 on the endogenous expression of TFPI. To overcome these limitations, we performed
reporter gene experiments to analyze the impact of the two forms of MAST2 on TFPI pro-
moter activity. TFPI promoter activity was lower in cells overexpressing MAST2 Gln89 than in
those overexpressing wild type MAST2. This suggests that the MAST2-dependent downregu-
lation of TFPI transcription is increased by the mutation. The amount of PAI-1 produced by
ECV304 cells, that can be easily measured by ELISA in the conditioned culture media, was
increased by the overexpression of MAST2 Gln89. Coherently, reporter gene experiment
shows that SERPINE1 promoter activity was higher in cells overexpressing MAST2 Gln89 than
in those overexpressing wild type MAST2. These results show that MAST2 Gln89 is more effi-
cient in stimulating SERPINE1 expression than wild-type MAST2. Although PLAU expression
is regulated by MAST2, the lack of significant differences in urokinase plasma levels between
control individuals and patients with MAST2 Gln89 variant suggests that it is not sensitive to
the Arg89Gln variant. The MAST2-dependent regulation of RHBDL2 expression and the
impact this could have on thrombomodulin shedding is currently under investigation. How-
ever, soluble thrombomodulin plasma levels were not different between control individuals
and patients (4.29 +/- 0.17 ng/mL vs 9.63 +/- 3.09 ng/mL respectively, p = 0.33), suggesting
that in this particular context, modification of thrombomodulin cleavage by RHBDL2 is not
sufficient to affect soluble thrombomodulin plasma level.
Overall, these data reveal that MAST2 mutation is actively involved in the alterations of
TFPI and PAI-1 expressions and would contribute to the pro-thrombotic state associated with
this variant.
The roles of MAST2 in cell biology and/or pathophysiology remain largely unexplored.
However, the relationship between MAST2 and PTEN is probably the aspect that has been
most studied in the literature. It has been previously demonstrated that MAST2 can bind to
and in vitro phosphorylate PTEN in its C-terminal tail [10,19], suggesting that PTEN may be a
physiological substrate for MAST2. PTEN dephosphorylates PIP3 and acts as a negative regula-
tor of PI3K/AKT signaling. It is known that C-terminal phosphorylation of PTEN decreases its
phosphatase activity, therefore contributing to higher PI3K/AKT signaling [20,21]. We consid-
ered the phosphorylation of AKT as a readout of PTEN activity and we detected more phos-
phorylated AKT Ser473 when MAST2 Gln89 was overexpressed, suggesting that MAST2
Gln89 phosphorylates/inhibits PTEN with increased efficiency compared with wild type
MAST2. Another point of view is that the MAST2/PTEN interaction allows the recruitment/
stabilization of PTEN at the plasma membrane [22,23], which allows the dephosphorylation of
PIP3 and ultimately the dephosphorylation of AKT. In this context, we hypothesized that
MAST2 Gln89 would have a reduced efficiency in recruiting PTEN at the plasma membrane.
Therefore, our results show that MAST2 Gln89 is involved in the etiology of VTE likely by
interfering with the haemostatic balance of endothelial cells (alteration of the of PAI-1 and
TFPI expression) on the one hand and with the phosphorylation of AKT on the other. Whether
MAST2 Gln89-dependent dysregulation of endothelial PTEN/PI3K/AKT axis is responsible for
the altered expression of PAI-1 and TFPI and whether it is involved in the etiology of VTE, is
beyond the scope of this work and deserves further investigation. However, it is important to
note that the role of the PTEN/PI3K/AKT axis in VTE is not fully understood. For example,
depending on the model studied, PTEN has either pro or antithrombotic properties [24,25].
The strength of the present study lies in the careful selection of the family studied. We
selected relatives (across three generations) of a family with a very strong clinically prothrom-
botic phenotype and no detectable known inherited thrombophilia in order to increase our
chance to identify new inherited thrombophilia that are likely to be rare. A special attention
has been paid to identify, in this family, cases with a strong personal and certain (documented)
history of VTE who are likely to have an underlying new inherited thrombophilia and controls
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with no coagulation abnormalities. As with any WES project, this strategy relies on the
assumption that the variants to be identified reside in coding or untranslated regions, a realis-
tic hypothesis, for at least some variants, since all thrombophilia anomalies identified so far are
located in such regions. It is demonstrated that patients with unprovoked VTE at young age
are more likely to have genetic risk factors of VTE. This family was also located in a geographi-
cally limited area, the Finistère department in Brittany: such families are rare, genetically
poorly mixed with people outside of Brittany and more likely to share common genes from
this geographical area.
Several limitations must be acknowledged: MAST2 mainly locates to the cytosol and it is
then unclear how it could be directly involved in the regulation of TFPI and SERPINE1 gene
expressions. Moreover, out of the 15 subjects from the family studied, plasma samples were
available in only 10 (3 cases and 7 controls). Further experimental studies are mandatory to
decipher the underlying mechanisms. Another is about the lack of generalizability of the result.
Indeed, we found no mutated patients in more than 6700 genotyped VTE patients suggesting
that the mutation is private as observed with the FIX Padua [26]. However, our results pave
the way for adding MAST2 to the list of genes to be sequenced and looked for in thrombophilia
families with unprovoked VTE. More importantly, our study uncovers a new regulatory path-
way of TFPI and SERPINE1 expression by MAST2.
In conclusion, using a whole exome sequencing approach in a large pedigree affected with
VTE, we identified an extremely rare variant in the Microtubule-associated serine/threonine-
protein kinase-2 (MAST2) gene, that is responsible for inherited thrombophilia through a not




The study was approved by the Ethics Committee ‘OUEST VIII’ (n˚ CPP Ouest 6–584; n˚-
Afssaps B91453-80). All individuals included in the research signed a written informed con-
sent to participate to the research.
Recruitment of the family
Patient recruitment and her family members have been prospectively performed since 2010 in
Finistère (France). This family has been carefully selected from the index case with acute VTE
and the following predefined criteria: a) VTE occurred at young age (< 50 years); b) was docu-
mented (i.e.; symptomatic proximal deep vein thrombosis and/or symptomatic pulmonary
embolism objectively diagnosed according to validated criteria)[27,28]; c) was unprovoked
(i.e.: VTE was not associated with clinical risk factors such as surgery, trauma or prolonged
immobilization (�72 hours) in the past 3 months, cancer in the past 2 years, chronic inflam-
matory illness, autoimmune disease, pregnancy, estrogen-containing pills, hormone replace-
ment therapy); and d) with no established biological risk factors (antithrombin, protein C,
protein S deficiencies, FV Leiden, prothrombin G20210A, lupus anticoagulant, anticardiolipin
antibodies). This proband should also have at least two family members across three genera-
tions with a previous history of symptomatic documented VTE with the same characteristics.
All relatives (with or without history of VTE) have been invited to participate to the study
excepted family members who were adopted or less than 16 years. All the participants have
been asked to come to the Brest clinical center, at the CIC INSERM 1412, for clinical and bio-
logical screening of VTE. A predefined standardized form has been used to collect clinical data
(demographic and clinical past history data, complete phenotype in the case of previous
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thrombosis, complete pedigree across three generations) and an extensive analysis of blood
coagulation has been performed. Clinical characteristics of the subjects are reported in
Table 2. A biobank including DNA, RNA, serum or citrate plasma samples stored at -80˚C was
set up for each family member.
Measurement of coagulation and fibrinolytic traits
Several coagulation and fibrinolytic parameters, not belonging to the classical thrombophilia
screening, were measured in 10 family members with plasma available (3 cases and 7 controls).
The 3 cases were on warfarin whereas none of the controls were on anticoagulant treatment at
the time of the sampling.
Activated partial thrombin time (aPTT) and prothrombin time (PT), fibrinogen, factor II,
factor V and factor X were measured in plasma with automated coagulometers (STA-Revolu-
tion, Diagnostica Stago, Asnières, France) using established commercial assays. Free tissue fac-
tor pathway inhibitor (f-TFPI) plasma levels were measured with the Asserachrom Free TFPI
enzyme immunoassay from Diagnostica Stago (Asnieres, France) and plasma PAI-1 activity
with the Zymutest PAI-1 activity from Hyphen Biomed (Neuville-sur-Oise, France). Uroki-
nase (uPA) plasma levels were measured with the uPA ELISA kit (Abcam, Cambrige, UK).
The euglobulin clot lysis time (ECLT) assay has been performed as previously described [29].
DNA analysis
Fifteen family members were studied (see genealogical tree in Fig 1). Relatives with a previous
VTE event as defined by our inclusion criteria were considered as cases. From 5 cases with
DNA available, 4 were selected for being whole exome sequenced. These were the most distant
VTE relatives. From the remaining family members who have not had any previous episode of
venous or arterial thrombosis and that presented with normal thrombin generation test and a
normal leg doppler ultrasound (individuals considered as controls), we selected for WES two
that were expected to be as genetically close as possible from cases (Fig 1). Clinical characteris-
tics of the WES participant are shown in Table 2.
A 2 × 100 paired-end sequencing was performed on an Illumina HiSeq2000 instrument at
the IGBMC platform (http://www.igbmc.fr/).
Bioinformatic WES workflow
FastQ sequences were aligned to the hs37d5 version of the human reference genome hg37
with BWA-MEM algorithm [30] of the Burrows-Wheeler Aligner.
Table 2. Clinical characteristics of the cases (i.e.; with VTE) in family members.
Cases number Gender Relationship WES Age at VTE (years) VTE type
305000 Female Index case Selected for WES 34 PE
305001 Female Mother Selected for WES 27 DVT
45 PE
54 PE
305002 Male Maternal uncle Selected for WES 32 DVT
36 PE + DVT
305003 Female Maternal aunt Selected for WES 43 PE + DVT
305012 Female Maternal Selected for replication 35 PE
PE: Pulmonary Embolism; DVT: deep vein thrombosis
https://doi.org/10.1371/journal.pgen.1009284.t002
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All duplicated reads were marked using picard-tools-v1.119 (http://broadinstitute.github.
io/picard/) and sorted using samtools-v1.3.1[31]. Base quality check was performed prior to
the variant calling with GATK—BaseRecalibrator (GenomeAnalysisTK-v3.3–0).
Single nucleotide variants (SNVs) and small insertions/deletions (INDELs) were called fol-
lowing GATK’s Best Practices (https://software.broadinstitute.org/gatk/best-practices) with
HaplotypeCaller. After the GATK’s VQSR step, «PASS» variants were annotated using
ANNOVAR[32] package.
As a strategy to identify the culprit variant, we first prioritized variants that were likely func-
tional (stop loss/stop gain, frameshift insertion/deletion, non-synonymous and splicing vari-
ants) and that were carried by all VTE cases and not by any of the two controls. Second, a
bioinformatics search in public genomic data repositories (eg dbSNP, NCBI, Ensembl, 1000
genomes, GnomAD (https://gnomad.broadinstitute.org/) and FrEx (http://lysine.univ-brest.
fr/FrExAC/) was carried out on prioritized variants to select as suggestive candidates those
that have not been reported, or reported to be at low frequencies (<1‰). We also took into
account the predicted deleteriousness of selected candidates using in silico tools such as SIFT,
PolyPhen and CADD-v1.2 [33] to further reduce the number of candidates.
Candidate variants identified from this multi-step strategy were then genotyped in all fam-
ily members for whom DNA was available, including an additional set of 1 case and 8 controls
beyond the initial group of individuals that were part of the WES experiment.
Validation of the impact of the newly identified variants in other cohorts of
patients with VTE
Identified candidate variants were genotyped in additional samples of VTE patients and
healthy individuals in order to get a more accurate estimation of their allele frequencies and
more evidence for the putative one. Several French studies for VTE were investigated. These
were:
- the “FIT study”, a prospective trans-sectional cohort assessing the risk of VTE in 2617
first-degree relatives of 507 index cases with VTE (507 families). In these families about 73% of
VTE events were unprovoked. Description of the cohort has been previously reported [34].
- the MARTHA, FARIVE and EDITH case-control studies for VTE, totaling 4,173 VTE
cases and 5,970 healthy individuals whose detailed description has already been reported else-
where [5]. Percentages of unprovoked VTE events were 27%, 29% and 100% in MARTHA,
FARIVE and EDITH respectively.
We retrieved information about variant rs1387081220 from large scale genotyping projects
which, in aggregate, included information from 345,939 genetically independent individuals,
with 60.26%, 12.51% and 12.35% being of Caucasoid, Asian and African ethnicity groups
respectively. A single copy of the minor allele of rs1387081220 was observed in two female
individuals from the gnomAD dataset (one Caucasian and one African) but was unobserved
in the remaining 345,937 individuals across all collections. However, no phenotype informa-
tion could be obtained from the gnomAD participants. The results of the look-up of genotypes
is summarised in S2A and S2B Table.
Functional characterization of the newly identified genetic variants
The role of MAST2 in endothelial function was assessed by small interference RNA (siRNA)
silencing. Comparison of the endothelial transcriptome of ECV304 cells cotransfected with
two MAST2 siRNA leading to a significant downregulation of MAST2 expression (around
80% reduction of mRNA levels) compared to ECV304 cells transfected with control siRNA
was performed using RNA-Seq.
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Total RNA extracted from transfected ECV304 cells with control or Mast2 siRNA were
used to prepare libraries using the NEBNex Ultra II Direction RNA library prep kit for Illu-
mina protocol according to supplied recommendations. Libraries were sequenced on an Illu-
mina NovaSeq instrument using a paired end sequencing of 2 x 100bp. Sequencing and
bioinformatics analysis of sequenced data were outsourced at the Integragen company
(https://www.integragen.com/). Base calling was performed using Illumina Real Time Analysis
(3.4.4) with default parameters. Fastq files were aligned to the reference Human genome hg38
with STAR [35] with the following parameters:—twopassMode Basic—outReadsUnmapped
None—chimSegmentMin 12—chimJunctionOverhangMin 12 -alignSJDBoverhangMin 10—
alignMatesGapMax 200000—alignIntronMax 200000 -chimSegmentReadGapMax parameter
3—alignSJstitchMismatchNmax 5–1 5 5—quantMode GeneCounts—outWigType wiggle—
sjdbGTFtagExonParentGene gene_name). Reads mapping to multiple locations were
removed. Gene expression were quantified using the full Gencode v31 annotation. STAR was
also used to obtain the number of reads associated to each gene in the Gencode v31 database
(restricted to protein-coding genes, antisense and lincRNAs). The Bioconductor DESeq pack-
age [36] was used to import raw counts for each sample into R statistical software and extract
the corresponding count matrix. After normalizing for library size, the count matrix was nor-
malized by the coding length of genes to compute FPKM scores (number of fragments per
kilobase of exon model and millions of mapped reads).
Plasmid constructs
Human TFPI promoter Firefly-luciferase reporter (TFPI-Luc), a pGL3-Basic vector containing
a fragment of TFPI promoter from -1224 to +45, was previously described [37]. SERPINE1
promoter (-483/+75) [38] was PCR amplified from THP1 genomic DNA then inserted in
place of the CMV promoter in the pd4EGFP plasmid (Clontech) that contains the sequence
coding for a destabilized version of EGFP. The resulting vector was named SERPINE1-dEGFP.
GFP-tagged MAST2 expression vector (RG206492 form Origene) was used as template to
PCR amplify only the full-length coding sequence of MAST2 (without the GFP coding
sequence), which was then cloned into pCDNA3 vector using the In-Fusion PCR cloning sys-
tem (Clontech).
Cell culture and transfection
HEK293 cells (Griptite 293 MSR) were from Thermo Fisher Scientific. ECV304 endothelial
[39] cells were from ATCC. The cells were maintained in culture as described by the manufac-
turers. Transfections of plasmid DNA were performed with PolyJet reagent (SignaGen Labora-
tories, Rockville, MD, USA). Transfections of siRNA alone or in association with plasmid
DNA were performed with JetPRIME reagent (Polyplus transfection), as specified by the man-
ufacturers. MAST2 specific siRNA (#4392420; ID: s42 and # AM51331; ID: 975) and negative
control siRNA were from Thermofisher.
Western blot
Identical amounts of total protein were heat-denatured and reduced (70˚C; 10min) then sub-
mitted to SDS-PAGE separation on 4–12% gradient NuPAGE gels (Life Technologies, Saint
Aubin, France) and transferred to polyvinylidene fluoride membranes. The membranes were
blocked for 1 hour in 5% BSA solution and incubated with the appropriate primary and HRP-
conjugated secondary antibodies (1:1,000 and 1:10,000 dilution, respectively). Immunodetec-
tions were performed using ECL reagent and image acquisition was performed by using a
chemiluminescent CCD imager ImageQuant LAS 4000 (GE Healthcare, Velizy-Villacoublay,
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France). Densitometric analysis of the bands was performed with the ImageQuant TL software
(GE Healthcare). MAST2 antibody (ab209079) was from Abcam, PTEN (138G6), AKT
(C67E7), phospho-AKT Ser473 (193H12) and β-actin (13E) antibodies PTEN were from Cell
Signaling Technology.
Gene reporter experiments
Promoter activities were measured 48 hours after cell transfection. For the study of SERPINE1
promoter activity assay, HEK293 cells transfected with human SERPINE1-dEGFP were
detached by incubation in PBS without calcium and magnesium and EGFP fluorescence was
measured by flow cytometry (Accuri C5, BD Biosciences). SERPINE1 promoter activity was
calculated as the means of fluorescence corrected for the value obtained with cells transfected
with an empty vector and expressed as fold change compared to the control situation. For the
study of TFPI promoter activity assay, HEK293 cells were cotransfected with human TFPI-Luc
and SV40-driven Renilla luciferase coding vectors. Firefly and Renilla luciferase were mea-
sured in cell lysates using a luminometer (EnSight Multimode plate reader, Perkin Elmer).
TFPI promoter activity was calculated as the ratio Firefly/Renilla luciferase and expressed as
fold change compared to control.
Real-Time PCR analysis
Total RNA was extracted using the Nucleospin RNA Kit (Macherey-Nagel, Hoerdt, France),
cDNA was synthesized from 0.5 μg of RNA using M-MLV reverse transcriptase (Life Technol-
ogies, Saint Aubin, France) and used for PCR amplification. RT-PCR were performed on the
LightCycler 480 instrument (Roche Applied Science, Meylan, France) using the Eva Green
MasterMix (Euromedex, Souffelweyersheim, France). The comparative Ct method (2-(ΔΔCT))
was used to calculate the relative differences in mRNA expression. The acidic ribosomal phos-
phoprotein P0 was used as housekeeping gene. Primers sequences are available upon request.
Changes were normalized to the mean of control values, which were set to 1.
Statistical analyses
All data but RNA sequencing data were analyzed with GraphPad Prism software and individ-
ual statistical two-sided tests used are identified in the figure legends. P values� 0.05 were con-
sidered statistically significant.
Differential analysis of RNA Seq data was performed using the Bioconductor limma pack-
age [40] on voom-transformed data in order to identify gene expression levels impacted by
MAST2 siRNA silencing. A False Discovery Rate (FDR) threshold of 1% was used to identify
candidate mRNAs associated with MAST2 knockdown. A functional enrichment analysis
using the Database for Annotation, Visualization and Integrated Discovery software (DAVID;
[41]), was performed on the most dysregulated genes to get insight into the biological path-
ways perturbated by MAST2 knockdown. For this analysis, the GO, KEGG, REACTOME, and
PANTHER databases were interrogated. The String database [https://string-db.org/cgi/input.
pl] and the Genemania (https://genemania.org/) text mining search tools were also used to
identify potential biological relationships between identified candidate mRNAs.
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